Westpac Banking Corp lowered its stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 4.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,428 shares of the medical instruments supplier’s stock after selling 2,000 shares during the quarter. Westpac Banking Corp owned approximately 0.06% of West Pharmaceutical Services worth $5,060,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Advisor Group Inc. boosted its position in West Pharmaceutical Services by 7.8% during the second quarter. Advisor Group Inc. now owns 18,033 shares of the medical instruments supplier’s stock worth $2,257,000 after purchasing an additional 1,299 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in shares of West Pharmaceutical Services by 1.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 13,720 shares of the medical instruments supplier’s stock valued at $1,717,000 after acquiring an additional 220 shares during the period. Aperio Group LLC boosted its position in shares of West Pharmaceutical Services by 2.2% in the second quarter. Aperio Group LLC now owns 44,876 shares of the medical instruments supplier’s stock valued at $5,616,000 after acquiring an additional 955 shares during the period. Dupont Capital Management Corp boosted its position in shares of West Pharmaceutical Services by 47.5% in the second quarter. Dupont Capital Management Corp now owns 11,731 shares of the medical instruments supplier’s stock valued at $1,468,000 after acquiring an additional 3,776 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of West Pharmaceutical Services by 4.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,454 shares of the medical instruments supplier’s stock valued at $557,000 after acquiring an additional 187 shares during the period. Institutional investors own 91.76% of the company’s stock.

A number of research firms have recently commented on WST. William Blair began coverage on shares of West Pharmaceutical Services in a research report on Tuesday, April 23rd. They issued an “outperform” rating and a $112.16 price objective for the company. Bank of America upgraded shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research report on Friday, July 26th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a research report on Saturday, August 3rd. Finally, Jefferies Financial Group lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 price objective for the company. in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $130.72.

Shares of WST stock traded up $1.32 during trading hours on Friday, reaching $144.20. The stock had a trading volume of 1,558 shares, compared to its average volume of 416,265. The stock’s fifty day simple moving average is $130.37 and its 200 day simple moving average is $116.89. The company has a current ratio of 3.02, a quick ratio of 2.27 and a debt-to-equity ratio of 0.18. West Pharmaceutical Services Inc. has a 12 month low of $91.75 and a 12 month high of $145.14. The firm has a market capitalization of $10.70 billion, a PE ratio of 51.33, a PEG ratio of 4.13 and a beta of 1.30.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.17. The business had revenue of $469.70 million for the quarter, compared to the consensus estimate of $459.90 million. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. West Pharmaceutical Services’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm posted $0.70 earnings per share. As a group, equities research analysts anticipate that West Pharmaceutical Services Inc. will post 3.07 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 6th. Investors of record on Wednesday, October 23rd will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date is Tuesday, October 22nd. West Pharmaceutical Services’s dividend payout ratio is currently 21.35%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: What is a CD ladder?

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.